Key result
Baseline lifestyle and medications show no cardiometabolic link, but minority patients see ~3 mmol/mol HbA1c rise.
Why the study?
The first episode of psychosis is a critical period for the emergence of cardiometabolic risk, but the influence of lifestyle, medication, and ethnicity on these outcomes is unclear.
Do lifestyle factors, medication, and ethnicity influence cardiometabolic risk in the year following the first episode of psychosis?
Cohort (n=293)
Yes
Do lifestyle factors, medication, and ethnicity influence cardiometabolic risk in the year following the first episode of psychosis?
Absolute Event Rate: 3.3% vs 0%
p-value: p=<0.01
Cardiometabolic risk, including obesity and glucose dysregulation, worsens significantly in the first year following a first episode of psychosis, with notable ethnic disparities in HbA1c progression.
No takes yet. Share an insight, caveat, or question.
Cardiometabolic risk rises in first-episode psychosis independent of lifestyle or antipsychotics; leaves open ethnic differences and prevention targets for trials.
Gaughran et al. (2019) conducted a cohort in First-episode psychosis (n=293). Lifestyle factors, antipsychotic medication, and ethnicity vs. Unexposed/reference groups (e.g., White ethnicity, different lifestyle habits) was evaluated on Change in median HbA1c over 12 months by ethnicity (p=<0.01). In patients with first-episode psychosis, baseline lifestyle and medication were not associated with 1-year cardiometabolic outcomes, but median HbA1c rose significantly by 3.3 mmol/mol in Black and minority ethnic groups compared to no change in White patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: